|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-5-11
|
|
pubmed:abstractText |
Pegylated interferon (IFN)-alpha plus ribavirin is the most effective treatment of chronic hepatitis C but has unpleasant side effects and high costs. A large proportion of patients do not respond to therapy for reasons that are unclear. We used gene expression profiling to investigate the molecular basis for treatment failure.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0016-5085
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
128
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1437-44
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15887125-Adult,
pubmed-meshheading:15887125-Antiviral Agents,
pubmed-meshheading:15887125-Drug Resistance, Viral,
pubmed-meshheading:15887125-Drug Therapy, Combination,
pubmed-meshheading:15887125-Female,
pubmed-meshheading:15887125-Hepatitis C, Chronic,
pubmed-meshheading:15887125-Humans,
pubmed-meshheading:15887125-Interferon-alpha,
pubmed-meshheading:15887125-Liver,
pubmed-meshheading:15887125-Male,
pubmed-meshheading:15887125-Middle Aged,
pubmed-meshheading:15887125-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:15887125-Polyethylene Glycols,
pubmed-meshheading:15887125-Recombinant Proteins,
pubmed-meshheading:15887125-Ribavirin
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.
|
|
pubmed:affiliation |
Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
